The long-term effect of elexacaftor/tezacaftor/ivacaftor on cardiorespiratory fitness in adolescent patients with cystic fibrosis: a pilot observational study
Language English Country Great Britain, England Media electronic
Document type Journal Article, Observational Study
PubMed
38807122
PubMed Central
PMC11134686
DOI
10.1186/s12890-024-03069-8
PII: 10.1186/s12890-024-03069-8
Knihovny.cz E-resources
- Keywords
- Cardiopulmonary exercise testing, Cystic fibrosis, Elexacaftor/tezacaftor/ivacaftor,
- MeSH
- Aminophenols * therapeutic use MeSH
- Benzodioxoles * therapeutic use MeSH
- Quinolones * therapeutic use MeSH
- Cystic Fibrosis * drug therapy physiopathology MeSH
- Child MeSH
- Drug Combinations * MeSH
- Indoles * therapeutic use MeSH
- Cardiorespiratory Fitness MeSH
- Humans MeSH
- Adolescent MeSH
- Pilot Projects MeSH
- Prospective Studies MeSH
- Pyrazoles * therapeutic use MeSH
- Pyridines * therapeutic use MeSH
- Pyrrolidines MeSH
- Pyrroles therapeutic use MeSH
- Oxygen Consumption MeSH
- Exercise Tolerance drug effects MeSH
- Exercise Test MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Names of Substances
- Aminophenols * MeSH
- Benzodioxoles * MeSH
- Quinolones * MeSH
- elexacaftor MeSH Browser
- Drug Combinations * MeSH
- Indoles * MeSH
- Pyrazoles * MeSH
- Pyridines * MeSH
- Pyrrolidines MeSH
- Pyrroles MeSH
BACKGROUND: Physical activity is a crucial demand on cystic fibrosis treatment management. The highest value of oxygen uptake (VO2peak) is an appropriate tool to evaluate the physical activity in these patients. However, there are several other valuable CPET parameters describing exercise tolerance (Wpeak, VO2VT1, VO2VT2, VO2/HRpeak, etc.), and helping to better understand the effect of specific treatment (VE, VT, VD/VT etc.). Limited data showed ambiguous results of this improvement after CFTR modulator treatment. Elexacaftor/tezacaftor/ivacaftor medication improves pulmonary function and quality of life, whereas its effect on CPET has yet to be sufficiently demonstrated. METHODS: We performed a single group prospective observational study of 10 adolescent patients with cystic fibrosis who completed two CPET measurements between January 2019 and February 2023. During this period, elexacaftor/tezacaftor/ivacaftor treatment was initiated in all of them. The first CPET at the baseline was followed by controlled CPET at least one year after medication commencement. We focused on interpreting the data on their influence by the novel therapy. We hypothesized improvements in cardiorespiratory fitness following treatment. We applied the Wilcoxon signed-rank test. The data were adjusted for age at the time of CPET to eliminate bias of aging in adolescent patients. RESULTS: We observed significant improvement in peak workload, VO2 peak, VO2VT1, VO2VT2, VE/VCO2 slope, VE, VT, RQ, VO2/HR peak and RR peak. The mean change in VO2 peak was 5.7 mL/kg/min, or 15.9% of the reference value (SD ± 16.6; p= 0.014). VO2VT1 improved by 15% of the reference value (SD ± 0.1; p= 0.014), VO2VT2 improved by 0.5 (SD ± 0.4; p= 0.01). There were no differences in other parameters. CONCLUSION: Exercise tolerance improved after elexacaftor/tezacaftor/ivacaftor treatment initiation. We suggest that the CFTR modulator alone is not enough for recovering physical decondition, but should be supplemented with physical activity and respiratory physiotherapy. Further studies are needed to examine the effect of CFTR modulators and physical therapy on cardiopulmonary exercise tolerance.
See more in PubMed
Cerny FJ, Pullano TP, Cropp GJ. Cardiorespiratory adaptations to exercise in cystic fibrosis. Am Rev Respir Dis. 1982;126(2):217–220. PubMed
Thin AG, Dodd JD, Gallagher CG, Fitzgerald MX, Mcloughlin P. Effect of respiratory rate on airway deadspace ventilation during exercise in cystic fibrosis. Respir Med. 2004;98(11):1063–1070. doi: 10.1016/j.rmed.2004.03.016. PubMed DOI
Regnis JA, Donnelly PM, Robinson M, Alison JA, Bye PT. Ventilatory mechanics at rest and during exercise in patients with cystic fibrosis. Am J Respir Crit Care Med. 1996;154(5):1418–1425. doi: 10.1164/ajrccm.154.5.8912758. PubMed DOI
Nixon PA, Joswiak ML, Fricker FJ. A six-minute walk test for assessing exercise tolerance in severely ill children. J Pediatr. 1996;129(3):362–366. doi: 10.1016/S0022-3476(96)70067-7. PubMed DOI
Pastré J, Prévotat A, Tardif C, Langlois C, Duhamel A, Wallaert B. Determinants of exercise capacity in cystic fibrosis patients with mild-to-moderate lung disease. BMC Pulm Med. 2014;14:74. doi: 10.1186/1471-2466-14-74. PubMed DOI PMC
Pianosi P, Pelech A. Stroke volume during exercise in cystic fibrosis. Am J Respir Crit Care Med. 1996;153(3):1105–1109. doi: 10.1164/ajrccm.153.3.8630552. PubMed DOI
Szollosi I, King SJ, Wilson JW, Naughton MT. Tachycardia in adults with cystic fibrosis is associated with normal autonomic function. Intern Med J. 2011;41(6):455–461. doi: 10.1111/j.1445-5994.2009.02039.x. PubMed DOI
Hebestreit H, Hulzebos EHJ, Schneiderman JE, Karila C, Boas SR, Kriemler S, et al. Cardiopulmonary Exercise Testing Provides Additional Prognostic Information in Cystic Fibrosis. Am J Respir Crit Care Med. 2019;199(8):987–995. doi: 10.1164/rccm.201806-1110OC. PubMed DOI
Edgeworth D, Keating D, Ellis M, Button B, Williams E, Clark D, et al. Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment. Clin Sci (Lond) 2017;131(15):2037–45. doi: 10.1042/CS20170995. PubMed DOI
Wilson J, You X, Ellis M, Urquhart DS, Jha L, Duncan M, et al. VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor/ivacaftor trial. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2021;20(3):499–505. doi: 10.1016/j.jcf.2020.12.006. PubMed DOI
Saynor ZL, Barker AR, Oades PJ, Williams CA. The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): an exercise physiology perspective. Pediatr Phys Ther Off Publ Sect Pediatr Am Phys Ther Assoc. 2014;26(4):454–461. PubMed
Savi D, Schiavetto S, Simmonds NJ, Righelli D, Palange P. Effects of Lumacaftor/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2019;18(3):420–424. doi: 10.1016/j.jcf.2019.03.001. PubMed DOI
Ahmed MI, Dayman N, Madge J, Gaillard E. P91 Cardiopulmonary exercise testing in CF adolescents after starting Tezacaftor/Ivacaftor. Thorax. 2021;76(Suppl 1):A136–A136.
Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809–1819. doi: 10.1056/NEJMoa1908639. PubMed DOI PMC
Snowball JE, Flight WG, Heath L, Koutoukidis DA. A paradigm shift in cystic fibrosis nutritional care: clinicians’ views on the management of patients with overweight and obesity. J Cyst Fibros. 2023;0(0). 10.1016/j.jcf.2023.03.011. PubMed
Causer AJ, Shute JK, Cummings MH, Shepherd AI, Wallbanks SR, Pulsford RM, et al. Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis. Pediatr Pulmonol. 2022;57(11):2652–2658. doi: 10.1002/ppul.26078. PubMed DOI PMC
Hebestreit H, Arets HGM, Aurora P, Boas S, Cerny F, Hulzebos EHJ, et al. Statement on exercise testing in cystic fibrosis. Respir Int Rev Thorac Dis. 2015;90(4):332–351. PubMed
Rysgaard UK, Pedersen CL, Jensen JH, Sørensen L, Philipsen LKD, Leo-Hansen C, et al. Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2022;21(5):844–849. doi: 10.1016/j.jcf.2022.05.009. PubMed DOI
Caterini JE, Ratjen F, Barker AR, Williams CA, Rendall K, Schneiderman JE, et al. Exercise intolerance in cystic fibrosis-the role of CFTR modulator therapies. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2022;21(2):282–292. doi: 10.1016/j.jcf.2021.11.011. PubMed DOI
Warth JD, Collier ML, Hart P, Geary Y, Gelband CH, Chapman T, et al. CFTR chloride channels in human and simian heart. Cardiovasc Res. 1996;31(4):615–624. doi: 10.1016/S0008-6363(95)00245-6. PubMed DOI
Robert R, Norez C, Becq F. Disruption of CFTR chloride channel alters mechanical properties and cAMP-dependent Cl- transport of mouse aortic smooth muscle cells. J Physiol. 2005;568(Pt 2):483–495. doi: 10.1113/jphysiol.2005.085019. PubMed DOI PMC
Lamhonwah AM, Bear CE, Huan LJ, Kim Chiaw P, Ackerley CA, Tein I. Cystic fibrosis transmembrane conductance regulator in human muscle: Dysfunction causes abnormal metabolic recovery in exercise. Ann Neurol. 2010;67(6):802–808. doi: 10.1002/ana.21982. PubMed DOI
Malik FA, Meissner A, Semenkov I, Molinski S, Pasyk S, Ahmadi S, et al. Sphingosine-1-phosphate is a novel regulator of cystic fibrosis transmembrane conductance regulator (CFTR) activity. PLoS One . 2015;10(6):e0130313. PubMed PMC
Madácsy T, Pallagi P, Maleth J. Cystic fibrosis of the pancreas: the role of CFTR channel in the regulation of intracellular Ca2+ signaling and mitochondrial function in the exocrine pancreas. Front Physiol. 2018;9:1585. doi: 10.3389/fphys.2018.01585. PubMed DOI PMC
Velsor LW, Kariya C, Kachadourian R, Day BJ. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Respir Cell Mol Biol. 2006;35(5):579–586. doi: 10.1165/rcmb.2005-0473OC. PubMed DOI PMC
van de Weert-van Leeuwen PB, Slieker MG, Hulzebos HJ, Kruitwagen CLJJ, van der Ent CK, Arets HGM. Chronic infection and inflammation affect exercise capacity in cystic fibrosis. Eur Respir J. 2012;39(4):893–898. doi: 10.1183/09031936.00086211. PubMed DOI
Casey M, Gabillard-Lefort C, McElvaney OF, McElvaney OJ, Carroll T, Heeney RC, et al. Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis. Thorax. 2023;78(8):835–839. doi: 10.1136/thorax-2022-219943. PubMed DOI
Divangahi M, Balghi H, Danialou G, Comtois AS, Demoule A, Ernest S, et al. Lack of CFTR in skeletal muscle predisposes to muscle wasting and diaphragm muscle pump failure in cystic fibrosis mice. PLoS Genet. 2009;5(7):e1000586. doi: 10.1371/journal.pgen.1000586. PubMed DOI PMC